Search company, investor...
OncoResponse company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Line of Credit | Alive

Total Raised


Last Raised

$50M | 7 mos ago

About OncoResponse

OncoResponse mines the human adaptive immune system to discover therapeutic antibodies against immuno-oncology targets. By identifying candidates from the immune systems of patients who have responded exceptionally well to cancer immunotherapies, OncoResponse has the potential to increase the success rate of these therapies across multiple cancer types.

OncoResponse Headquarters Location

1124 Columbia St Suite 300

Seattle, Washington, 98104,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing OncoResponse

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

OncoResponse is included in 3 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

OncoResponse Patents

OncoResponse has filed 3 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Experimental cancer drugs
  • Immune system
patents chart

Application Date

Grant Date


Related Topics




Monoclonal antibodies, Immune system, Clusters of differentiation, Immunology, Experimental cancer drugs


Application Date


Grant Date



Related Topics

Monoclonal antibodies, Immune system, Clusters of differentiation, Immunology, Experimental cancer drugs



Latest OncoResponse News

08:00 EDT OncoResponse Announces Clinical Supply Agreement with Regeneron to Evaluate OR2805 in Combination with Libtayo® (cemi...

Sep 7, 2022

News provided by Share this article Share this article SEATTLE, Sept. 7, 2022 /PRNewswire/ -- OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of elite cancer responders, today announced a clinical supply agreement with Regeneron for PD-1 inhibitor Libtayo® (cemiplimab). The supply agreement will support the evaluation of Libtayo in combination with OR2805, a fully human monoclonal antibody identified from an elite cancer responder using OncoResponse's proprietary B-cell discovery platform. "We believe the ability of OR2805 to potently activate myeloid cells within the tumor microenvironment will not only provide benefit as a monotherapy, but also improve responses to currently available checkpoint inhibitor immunotherapies such as Libtayo," said Bob Lechleider, MD, Chief Medical Officer of OncoResponse. "We look forward to evaluating the combination of OR2805 with Libtayo, which has demonstrated efficacy in pivotal trials, serving as the basis for FDA approval in three types of advanced cancers. We believe that this combination treatment approach has the potential to improve the outcomes of patients with cancer." OR2805 is being evaluated in an ongoing Phase 1 study examining safety, pharmacokinetics and preliminary anti-cancer activity in patients with advanced solid tumors alone and in combination with anti-PD-1 therapy. The trial includes a dose escalation phase, followed by several expansion cohorts. The role of potential biomarkers will be evaluated throughout the study, and more intensively in a separate biology cohort.  identifier: NCT05094804 About OR2805 OR2805 is a fully human antibody discovered using B cells derived from an elite responder to checkpoint inhibitor (CPI) therapy. This antibody binds to CD163 which is highly expressed on tumor associated macrophages (TAMs) that create an immunosuppressive tumor microenvironment and inhibit anti-tumor T-cell responses. High frequency of CD163-expressing TAMs generally predicts an unfavorable prognosis in solid tumors. OR2805 is designed to improve anti-tumor T-cell responses, by reversing the immunosuppression of TAMs, as a therapeutic strategy for monotherapy and in combination with CPI. About OncoResponse OncoResponse is a clinical-stage, immuno-oncology biotech company developing cancer immunotherapies using clues from the immune systems of elite cancer responders. In a broad strategic alliance with MD Anderson Cancer Center, OncoResponse deploys a proprietary B-cell discovery platform to identify and develop novel therapeutics targeting the tumor microenvironment. The company's lead candidate, OR2805, has entered clinical studies. OR2805 is a fully human antibody discovered using B cells derived from an elite responder to checkpoint inhibitor (CPI) therapy. Additional pipeline candidates that modulate suppressive macrophage activity are under development. OncoResponse is a privately held company backed by investment from MD Anderson Cancer Center, Rivervest Venture Partners, Qatar Investment Authority, Redmile Group, Magnetar Group, Yonjin Venture, InterVest, Bering Capital, ARCH Venture Partners, Helsinn Investment Fund, Canaan Partners, GreatPoint Ventures, Takeda Ventures, Buchang Pharma, Alexandria Real Estate Equities and William Marsh Rice University. For more information please visit and follow us on LinkedIn and Twitter . Media Contact:

OncoResponse Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

OncoResponse Rank

  • When was OncoResponse founded?

    OncoResponse was founded in 2015.

  • Where is OncoResponse's headquarters?

    OncoResponse's headquarters is located at 1124 Columbia St, Seattle.

  • What is OncoResponse's latest funding round?

    OncoResponse's latest funding round is Line of Credit.

  • How much did OncoResponse raise?

    OncoResponse raised a total of $153.1M.

  • Who are the investors of OncoResponse?

    Investors of OncoResponse include Oxford Finance, 3B Future Health Fund, ARCH Venture Partners, Canaan Partners, Redmile Group and 14 more.

  • Who are OncoResponse's competitors?

    Competitors of OncoResponse include Epsilogen, Immune-Onc Therapeutics, Fortis Therapeutics, Pionyr Immunotherapeutics, Neon Therapeutics and 9 more.

You May Also Like

ImmunoMet Therapeutics

ImmunoMet Therapeutics is a development-stage biotechnology company focused on utilizing cellular metabolism to develop anti-tumor and immuno-oncology therapies.

Immune-Onc Therapeutics Logo
Immune-Onc Therapeutics

Immune-Onc Therapeutics is a privately held cancer immunotherapy company dedicated to the discovery and development of biologic treatments for cancer patients. The company aims to translate scientific insights in the tumor microenvironment and immune suppressive pathways to develop biotherapeutics.

Fortis Therapeutics

Fortis Therapeutics is an immuno-oncology biotech company focused on developing new antibody-drug conjugate therapies for late-stage multiple myeloma and late-stage prostate cancer. Fortis was founded based on technology exclusively licensed from UCSF and developed in the laboratory of Bin Liu, Ph.D.

Pionyr Immunotherapeutics Logo
Pionyr Immunotherapeutics

Pionyr Immunotherapeutics is developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity. The company is exploiting target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics. The company’s approach, Myeloid Tuning, is designed to enhance the immune system’s anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity.

Macrophage Pharma Logo
Macrophage Pharma

Macrophage Pharma is an immuno-oncology company focused on the discovery and development of novel therapies designed to enhance anti-tumour immune responses. The Company's technology platform is designed to deliver small molecule drugs to tumour associated macrophages in a highly selective manner to activate the body's natural immune system to fight cancer.


Epsilogen is engaged in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE has several key features that make it ideal for the treatment of solid tumors including greater potency, enhanced tumor access, and a long tissue half-life.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.